Pazufloxacin (mesylate)

Pazufloxacin mesylate is an orally active fluoroquinolone antimicrobial agent. Pazufloxacin mesylate inhibits DNA gyrase with IC50 values of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa) . Pazufloxacin mesylate exhibits broad-spectrum antimicrobial activity, with MIC90 values ranging from 0.025 to 100 μg/mL against Gram-positive and Gram-negative bacteria, non-fermenting bacteria, Legionella spp., and anaerobic bacteria. Pazufloxacin mesylate is indicated for research on systemic infections, lung infections, urinary tract infections, and Legionella pneumonia[1][2][3][4][5].

Product Specifications

CAS Number

[163680-77-1]

Product Name Alternative

T-3762; Pazufloxacin methanesulfonate; Pazufloxacin mesilate

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Bacterial; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Pazufloxacin-mesylate.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C(C(C1=O)=CN2[C@@H](C)COC3=C(C4(N)CC4)C(F)=CC1=C23)O.CS(=O)(O)=O

Molecular Formula

C17H19FN2O7S

Molecular Weight

414.41

Precautions

H315, H319, H335

References & Citations

[1]Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37 (3) : p. 384-92.|[2]Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36 (10) : p. 2293-303.|[3]Takei M, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45 (12) :3544-7. |[4]Sousa J, et al. First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 1;930:104-11.|[5]Morinaga Y, et al. In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia. Exp Lung Res. 2010 Oct;36 (8) :484-90.